GlassScriptPhysician profile
Camilla F Flemate
NPI 1962638569
$17,941.64
in general payments reported to CMS, 2019-2025
31 companies · $4,337 in 2025
The $4,337 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,578 · 2022: $3,532 · 2023: $2,652 · 2024: $4,842 · 2025: $4,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,454.09 |
| Education | $377.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,498.52 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $2,317.25 | 2021-2025 | Dupixent |
| Janssen Biotech, INC. | $2,183.79 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $1,742.44 | 2021-2025 | |
| Incyte Corporation | $1,124.49 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $1,117.71 | 2021-2025 | Nemluvio, Dysport |
| Leo Pharma INC. | $903.70 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $820.96 | 2021-2025 | Absorica Ld, Winlevi |
| Pfizer INC. | $725.18 | 2021-2025 | |
| Lilly USA, LLC | $724.81 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| Arcutis Biotherapeutics, INC. | $545.32 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $541.00 | 2021-2025 | |
| Allergan, INC. | $413.55 | 2021-2022 | |
| Ucb, INC. | $346.79 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $291.97 | 2021-2025 | Otezla, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $280.69 | 2021-2025 | Klisyri |
| Revance Therapeutics, INC. | $233.53 | 2024-2025 | Daxi, Daxxify |
| E.R. Squibb & Sons, L.L.C. | $172.66 | 2022-2025 | Sotyktu |
| Sanofi-Aventis U.S. LLC | $139.26 | 2021-2024 | |
| Dermavant Sciences, INC. | $138.51 | 2023-2024 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $102.43 | 2021-2024 | Cabtreo, Arazlo, Jublia |
| Strata Skin Sciences, INC. | $100.99 | 2022-2024 | Xtrac |
| Merz North America, INC. | $97.05 | 2021-2023 | Xeomin |
| Vyne Pharmaceuticals INC. | $79.27 | 2021 | |
| Biofrontera INC. | $77.98 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $61.70 | 2025 | |
| Novartis Pharmaceuticals Corporation | $57.50 | 2024-2025 | |
| Mayne Pharma Commercial LLC | $44.62 | 2021 | |
| Epi Health, LLC | $20.36 | 2021 | |
| Genentech USA, INC. | $18.85 | 2023 | Xolair |
| Dermira, INC. | $18.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camilla Flemate listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.